17 results on '"Palmedo H"'
Search Results
2. Tc-99m labelled anti CD 66 antigranulocyte antibody imaging for assessment of bone marrow reserve.
- Author
-
Matthies A, Reinhardt M, Palmedo H, Ezziddin S, Abramowski B, Kuhn W, Biersack HJ, and von Mallek D
- Subjects
- Antibodies, Monoclonal, Antigens, CD immunology, Antigens, Differentiation immunology, Antineoplastic Agents adverse effects, Antineoplastic Agents therapeutic use, Bone Marrow Neoplasms complications, Carcinoma complications, Cell Adhesion Molecules, Chemotherapy, Adjuvant, Female, Humans, Middle Aged, Predictive Value of Tests, Radioimmunodetection methods, Risk Factors, Technetium, Bone Marrow diagnostic imaging, Bone Marrow physiology, Bone Marrow Neoplasms diagnostic imaging, Bone Marrow Neoplasms secondary, Breast Neoplasms drug therapy, Breast Neoplasms pathology, Carcinoma diagnostic imaging, Carcinoma secondary, Granulocytes immunology
- Abstract
Patients with metastatic disease to the bone marrow are at risk of significant hematologic toxicity, if they undergo myelotoxic chemotherapy. Tc-99m labelled Anti CD 66 monoclonal antibody imaging is a useful, noninvasive approach to the assessment of bone marrow reserve under such circumstances.
- Published
- 2005
3. FDG-PET in monitoring therapy of breast cancer.
- Author
-
Biersack HJ, Bender H, and Palmedo H
- Subjects
- Breast Neoplasms drug therapy, Breast Neoplasms radiotherapy, Clinical Trials as Topic, Decision Support Systems, Clinical, Drug Therapy methods, Female, Humans, Lymphatic Metastasis, Neoplasm Staging methods, Practice Guidelines as Topic, Practice Patterns, Physicians', Prognosis, Radiopharmaceuticals, Radiotherapy methods, Reproducibility of Results, Risk Factors, Sensitivity and Specificity, Treatment Outcome, Antineoplastic Agents therapeutic use, Breast Neoplasms diagnostic imaging, Breast Neoplasms therapy, Fluorodeoxyglucose F18, Positron-Emission Tomography methods, Risk Assessment methods
- Abstract
Fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET) has been used successfully for the staging and re-staging of breast cancer. Another significant indication is the evaluation of therapy response. Only limited data are available on the use of FDG-PET in breast cancer after radiation therapy. The same holds true for chemotherapy. Only the therapy response in locally advanced breast cancer after chemotherapy has been investigated thoroughly. Histopathological response could be predicted with an accuracy of 88-91% after the first and second courses of therapy. A quantitative evaluation is, of course, a prerequisite when FDG-PET is used for therapy monitoring. Only a small number of studies have focussed on hormone therapy. In this context, a flare phenomenon with increasing standardised uptake values after initiation of tamoxifen therapy has been observed. More prospective multicentre trials will be needed to make FDG-PET a powerful tool in monitoring chemotherapy in breast cancer.
- Published
- 2004
- Full Text
- View/download PDF
4. Locally advanced breast cancer: is PET useful for monitoring primary chemotherapy?
- Author
-
Biersack HJ and Palmedo H
- Subjects
- Chemotherapy, Adjuvant, Female, Humans, Breast Neoplasms diagnostic imaging, Breast Neoplasms drug therapy, Fluorodeoxyglucose F18, Tomography, Emission-Computed
- Published
- 2003
5. Breast cancer imaging with PET and SPECT agents: an in vivo comparison.
- Author
-
Palmedo H, Hensel J, Reinhardt M, Von Mallek D, Matthies A, and Biersack HJ
- Subjects
- Animals, Breast Neoplasms diagnostic imaging, Metabolic Clearance Rate, Muscle, Skeletal diagnostic imaging, Muscle, Skeletal metabolism, Neoplasm Transplantation, Radiometry methods, Radiopharmaceuticals pharmacokinetics, Rats, Rats, Sprague-Dawley, Reproducibility of Results, Sensitivity and Specificity, Tomography, Emission-Computed, Single-Photon methods, Breast Neoplasms metabolism, Fluorodeoxyglucose F18 pharmacokinetics, Technetium Tc 99m Dimercaptosuccinic Acid pharmacokinetics, Technetium Tc 99m Sestamibi pharmacokinetics, Tomography, Emission-Computed methods
- Abstract
Unlabelled: Several radiopharmaceuticals and imaging techniques are proposed for breast cancer imaging. Since limited data are available of the uptake of SPECT and PET radiopharmaceuticals in malignant breast tumors and their metastases the aim of this study was to compare the uptake values and to correlate these data with imaging findings., Methods: We have studied the uptake of F-18 FDG, Tc-99m MIBI and Tc-99m (V)DMSA in 31 tumors using immunosuppressed rats implanted with HH-16 clone 4 mammary tumor cells. Tumor gamma camera and PET imaging was performed to gain biokinetic data and uptake values by ROI-analysis., Results: Tumor uptake was highest for F-18 FDG > Tc-99m (V)DMSA > Tc-99m MIBI. The uptake ratios (tumor to muscle) correlated well with the ratios calculated by ROI-analysis determined by imaging., Conclusions: In this in-vivo model, F-18 FDG revealed the best uptake and imaging properties and may be the radiopharmaceutical of choice for routine breast cancer imaging.
- Published
- 2002
- Full Text
- View/download PDF
6. Improved diagnosis of advanced bone marrow metastases by means of radiolabeled antigranulocyte antibodies.
- Author
-
von Mallek D, Joe A, Palmedo H, Matthies A, Biersack HJ, and Reinhardt MJ
- Subjects
- Bone Marrow Neoplasms secondary, Breast Neoplasms pathology, Carcinoma, Ductal, Breast secondary, Female, Follow-Up Studies, Humans, Immunoglobulin G immunology, Middle Aged, Neoplasm Staging, Predictive Value of Tests, Radioimmunodetection methods, Reproducibility of Results, Sensitivity and Specificity, Bone Marrow Neoplasms diagnostic imaging, Breast Neoplasms diagnostic imaging, Carcinoma, Ductal, Breast diagnostic imaging, Granulocytes immunology, Radiopharmaceuticals, Technetium Tc 99m Medronate
- Abstract
Assessment of bone marrow metastases using Tc-99m-labeled antigranulocyte antibodies and Tc-99m-labeled nanocolloids is discussed in osseous metastasizing breast cancer. A 53-year-old patient with bone metastases of breast cancer (pT2 pN1biv cM1) developed leukocytopenia WHO Grade III following polychemotherapy. Bone marrow scintigraphy with Tc-99m labeled nanocolloids and Tc-99m-labeled antigranulocyte antibodies revealed pronounced bone marrow infiltration as the cause. Comparing both procedures, the images with antigranulocyte antibodies showed a clearly better bone marrow image, considerably higher contrast and almost no superimposition of the liver over the spine. In osseous metastasizing breast cancer, scintigraphy with Tc-99m-labeled antigranulocyte antibodies enables assessment of metastases in the entire bone marrow.
- Published
- 2002
7. What can we expect from MDR breast cancer imaging with sestamibi?
- Author
-
Palmedo H
- Subjects
- Breast Neoplasms chemistry, Female, Humans, Radionuclide Imaging, ATP Binding Cassette Transporter, Subfamily B analysis, Breast Neoplasms diagnostic imaging, Breast Neoplasms drug therapy, Drug Resistance, Multiple, Radiopharmaceuticals, Technetium Tc 99m Sestamibi
- Published
- 2002
8. Pain palliation with rhenium-186 HEDP in breast cancer patients with disseminated bone metastases.
- Author
-
Palmedo H, Bender H, Dierke-Dzierzon C, Carl UM, Risse J, Krebs D, and Biersack HJ
- Subjects
- Adult, Aged, Analgesics administration & dosage, Blood Cell Count, Bone Neoplasms blood, Bone Neoplasms diagnostic imaging, Etidronic Acid adverse effects, Female, Humans, Injections, Intravenous, Middle Aged, Pain Measurement, Radioisotopes adverse effects, Radionuclide Imaging, Rhenium adverse effects, Treatment Outcome, Bone Neoplasms secondary, Breast Neoplasms pathology, Etidronic Acid therapeutic use, Pain prevention & control, Palliative Care, Radioisotopes therapeutic use, Rhenium therapeutic use
- Abstract
Purpose: For patients with metastatic prostate cancer, first results have shown that rhenium-186 (Re-186) hydroxyethylidene diphosphonate (HEDP) is efficient in pain palliation of disseminated bone metastases. The aim of this study was to determine whether significant pain reduction can also be achieved in breast cancer patients with Re-186 HEDP., Methods: Thirty patients with breast cancer who had multifocal painful bone metastases received a total of 38 intravenous Re-186 HEDP injections. Pain relief was assessed through daily documentation of the visual analog scale and analgesic consumption. A significant response to treatment was determined if the visual analog scale or analgesic consumption decreased significantly for at least 2 weeks. Blood counts were controlled at baseline and at weeks 4 and 8., Results: A response to pain therapy was observed in 60% (18 of 30) of the patients. A reversible thrombocytopenia and leukopenia of grade 2 (according to World Health Organization criteria) was found in 4 and 2 patients, respectively., Conclusion: Patients with disseminated osseous metastases resulting from breast cancer can benefit from therapy with Re-186 HEDP.
- Published
- 1999
- Full Text
- View/download PDF
9. Remission of bone metastases after combined chemotherapy and radionuclide therapy with Re-186 HEDP.
- Author
-
Palmedo H, Grünwald F, Wagner U, Köhler S, Krebs D, and Biersack HJ
- Subjects
- Bone Neoplasms diagnostic imaging, Carcinoma, Ductal, Breast secondary, Carcinoma, Ductal, Breast therapy, Combined Modality Therapy, Female, Humans, Middle Aged, Radionuclide Imaging, Radiopharmaceuticals therapeutic use, Technetium Tc 99m Medronate, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Bone Neoplasms secondary, Bone Neoplasms therapy, Breast Neoplasms pathology, Etidronic Acid therapeutic use, Palliative Care methods, Radioisotopes therapeutic use, Rhenium therapeutic use
- Abstract
A patient with disseminated osseous metastases due to breast cancer reported multifocal pain. Because of persisting pain after a first cycle of chemotherapy, 1,295 MBq Re-186 HEDP was administered intravenously. Excellent pain relief was observed. Subsequently, the patient received further combined chemotherapy and Re-186 HEDP therapy and remained pain free. Tc-99m MDP bone imaging showed a significant regression of osseous metastases. It may be speculated that the combination of Re-186 HEDP and chemotherapy results in significantly increased palliation of metastatic bone disease.
- Published
- 1998
- Full Text
- View/download PDF
10. Scintimammography with technetium-99m methoxyisobutylisonitrile: results of a prospective European multicentre trial.
- Author
-
Palmedo H, Biersack HJ, Lastoria S, Maublant J, Prats E, Stegner HE, Bourgeois P, Hustinx R, Hilson AJ, and Bischof-Delaloye A
- Subjects
- Breast Neoplasms epidemiology, Female, Humans, Middle Aged, Predictive Value of Tests, Prospective Studies, ROC Curve, Radionuclide Imaging, Sensitivity and Specificity, Breast Neoplasms diagnostic imaging, Radiopharmaceuticals, Technetium Tc 99m Sestamibi
- Abstract
The aim of the trial was to determine the diagnostic accuracy of scintimmammography with technetium-99m methoxyisobutylisonitrile (99mTc-MIBI) in the detection of primary breast cancer and to verify its clinical usefulness. A total of 246 patients with a suspicious breast mass or positive mammogram were included in this prospective European multicentre trial. At 5 min and 60 min (optional) p.i. two lateral prone images were acquired for 10 min each; 30 min p.i. one anterior image was acquired for 10 min. There were 253 lesions (195 palpable and 58 non-palpable), in respect of which histology revealed 165 cancers and 88 benign lesions. Institutional and blinded read results were correlated to core laboratory histopathology results obtained during excisional biopsy. Diagnostic accuracy for the detection of breast cancer was calculated per lesion. The overall sensitivity and specificity of blinded read scintimammography were 71% and 69%, respectively. For palpable lesions, the sensitivity of blinded read and institutional read scintimammography was 83% and 91%, respectively. Sensitivity was not dependent on the density of the breast tissue. Invasive ductal and invasive lobular cancers showed similar sensitivity. The sensitivity and specificity of mammography were 91% and 42%, respectively, and did not depend on the tumour size. In 60% of false-negative mammograms, 99mTc-MIBI was able to diagnose malignancy (true-positive). High-quality imaging with 99mTc-MIBI has a high diagnostic accuracy for the detection of primary breast cancer. Used as a complementary method, scintimammography with 99mTc-MIBI can help to diagnose breast cancer at an earlier stage in patients with dense breasts.
- Published
- 1998
- Full Text
- View/download PDF
11. Results of the European multicenter study of radionuclide mammography with Tc-99m-MIBI.
- Author
-
Grünwald F, Palmedo H, Mallmann P, and Biersack HJ
- Subjects
- Europe, Female, Humans, Mammography, Middle Aged, Prospective Studies, Radionuclide Imaging, Sensitivity and Specificity, Technetium Tc 99m Sestamibi, Breast Neoplasms diagnostic imaging, Carcinoma, Ductal, Breast diagnostic imaging, Carcinoma, Lobular diagnostic imaging
- Abstract
In the European multicenter trial 246 female patients with suspicious mammographic result and/or breast mass were studied. In 253 lesions (195 palpable, 58 non-palpable) 165 malignant and 88 benign results were obtained histologically. All scans were evaluated centrally and institutionally. Central evaluation (per lesion) resulted in a sensitivity of 71% and a specificity of 69%. For palpable lesions, sensitivity was 83% in the central read and 91% in the institutional read. No difference was observed between invasive ductal and invasive lobular carcinoma. X-ray density had no influence on scintigraphic sensitivity. Sensitivity and specificity of mammography were 91% and 42%, respectively.
- Published
- 1998
12. [Pain therapy in multiple bone metastases in breast carcinoma with rhenium 186 HEDP].
- Author
-
Hauswirth AE, Palmedo H, Dierke-Dzierzon C, Biersack HJ, and Krebs D
- Subjects
- Bone Neoplasms diagnostic imaging, Bone Neoplasms radiotherapy, Breast Neoplasms diagnostic imaging, Female, Humans, Middle Aged, Pain Measurement, Quality of Life, Radionuclide Imaging, Treatment Outcome, Bone Neoplasms secondary, Breast Neoplasms radiotherapy, Etidronic Acid therapeutic use, Palliative Care, Radioisotopes therapeutic use, Rhenium therapeutic use
- Abstract
Therapeutic means for patients with disseminated painful bone metastases in breast cancer are strongly limited. There is a big need of an effective and well tolerated therapy. The aim of this study was to evaluate the efficacy of rhenium-186 HEDP for pain palliation in patients with bone metastases in breast cancer. 17 patients with painful bone metastases taking analgesics received one or more injections of 1295 MB9 rhenium-186 HEDP. In 59% of the patients the therapy resulted in a significant reduction of pain. The duration of pain relief partially hold on up to nine weeks. The main side effects of therapy were a short decrease of platelets and leucocytes and an increase of pain for 1-2 days. As conclusion we found out that therapy with rhenium-186 HEDP can be used complementarily to analgesic therapy and radiation in patients with painful disseminated bone metastases in breast cancer.
- Published
- 1998
13. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and technetium-99m methoxyisobutylisonitrile scintimammography in the detection of breast tumours.
- Author
-
Palmedo H, Bender H, Grünwald F, Mallmann P, Zamora P, Krebs D, and Biersack HJ
- Subjects
- Axilla, Breast Neoplasms epidemiology, Breast Neoplasms pathology, Female, Humans, Lymph Nodes diagnostic imaging, Lymphatic Metastasis, Middle Aged, Predictive Value of Tests, Sensitivity and Specificity, Tomography, Emission-Computed, Single-Photon, Breast Neoplasms diagnostic imaging, Fluorine Radioisotopes, Fluorodeoxyglucose F18, Radiopharmaceuticals, Technetium Tc 99m Sestamibi, Tomography, Emission-Computed
- Abstract
The aim of this study was to compare, in breast cancer patients, the diagnostic accuracy of positron emission tomography (PET) using fluorine-18 fluorodeoxyglucose (FDG) and scintimammography (SMM) using technetium-99m methoxyisobutylisonitrile (MIBI). A total of 20 patients (40 breasts with 22 lesions) were evaluated serially with MIBI and, on the following day, with FDG. For SMM, planar and single-photon emission tomography imaging in the prone position was performed starting at 10 min following the injection of MIBI (740 MBq). For PET, scans were acquired 45-60 min after the injection of FDG (370 MBq) and attentuation correction was performed following transmission scans. Results from SMM and PET were subsequently compared with the histopathology results. True-positive results were obtained in 12/13 primary breast cancers (mean diameter=29 mm, range 8-53 mm) with both FDG and MIBI. False-negative results were obtained in two local recurrences (diameter <9 mm) with both FDG and MIBI. In benign disease, FDG and MIBI did not localize three fibrocystic lesions, two fibroadenomas and one inflammatory lesion (true-negative), but both localized one fibroadenoma (false-positive). Collectively, the results demonstrate a sensitivity of 92%, and a specificity of 86%, for primary breast cancer regardless of whether FDG or MIBI was used. In contrast to MIBI scintigraphy, FDG PET scored the axillae correctly as either positive (metastatic disease) or negative (no axillary disease) in all 12 patients. The tumour/non-tumour ratio for MIBI was 1.97 (range 1.43-3.1). The mean standard uptake value (SUV) for FDG uptake was 2.57 (range 0.3-6.2). The diagnostic accuracy of SMM was equivalent to that of FDG PET for the detection of primary breast cancer. For the detection of in situ lymph node metastases of the axilla, FDG seems to be more sensitive than 99mTc-MIBI.
- Published
- 1997
- Full Text
- View/download PDF
14. Value of 18fluoro-deoxyglucose positron emission tomography in the staging of recurrent breast carcinoma.
- Author
-
Bender H, Kirst J, Palmedo H, Schomburg A, Wagner U, Ruhlmann J, and Biersack HJ
- Subjects
- Adult, Aged, Bone Neoplasms diagnostic imaging, Bone Neoplasms secondary, False Negative Reactions, False Positive Reactions, Female, Fluorine Radioisotopes, Fluorodeoxyglucose F18, Humans, Liver Neoplasms diagnostic imaging, Liver Neoplasms secondary, Lung Neoplasms diagnostic imaging, Lung Neoplasms secondary, Lymphatic Metastasis, Magnetic Resonance Imaging, Middle Aged, Neoplasm Metastasis, Neoplasm Recurrence, Local, Neoplasm Staging, Reproducibility of Results, Tomography, Emission-Computed, Breast Neoplasms diagnostic imaging, Breast Neoplasms pathology, Deoxyglucose analogs & derivatives
- Abstract
The aim of the study was to evaluate the feasibility of staging recurrent breast carcinoma employing fluorine-18-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) under routine clinical conditions. In 75 patients with suspected recurrent or metastatic disease, whole-body FDG-PET was performed and results correlated with morphological imaging (CT/MRI) data and verified by histological findings. FDG-PET correctly identified 16 patients with local recurrence, 28 with lymph node involvement, 15 with bone, 5 with lung and 2 with liver metastases. CT/MRI identified 10 patients with local recurrences, 17 with lymph node involvement, 6 with bone, 5 with lung and 1 with liver metastases. FDG-PET detected 6 local recurrences, 8 lymph node, and 7 bone metastases, which were not visualized by CT/MRI. Our data provide the basis for use of FDG-PET in the whole-body restaging of recurrent breast carcinoma in preselected patients under routine clinical conditions.
- Published
- 1997
15. Scintimammography with Tc-99m MIBI in patients with suspicion of primary breast cancer.
- Author
-
Palmedo H, Schomburg A, Grünwald F, Mallmann P, Boldt I, and Biersack HJ
- Subjects
- Adult, Aged, Breast Diseases diagnostic imaging, Breast Neoplasms pathology, Contrast Media, Diagnosis, Differential, Female, Humans, Lymph Nodes diagnostic imaging, Lymph Nodes pathology, Lymphatic Metastasis, Mammography methods, Middle Aged, Radionuclide Imaging, Breast Neoplasms diagnostic imaging, Technetium Tc 99m Sestamibi
- Abstract
The aim of the study was to evaluate the diagnostic accuracy of scintimammography with Tc-99m MIBI for the detection of breast cancer. Patients with a suspicious lesion detected by palpation or mammography were included in the study. Excisional biopsy was performed on all patients. Mammography was performed within 3 weeks prior to scintigraphy. All patients received 740 MBq Tc-99m MIBI intravenously in the arm contralateral to the suspicious breast and were subsequently examined in a prone position. At 5 to 10 min postinjection, planar images were obtained in lateral and anterior views, with an acquisition time of 10 min each. After planar imaging, a SPECT study was performed using a two-head camera. Breast cancer was confirmed in 29 out of 68 patients. The tumor size ranged from 6 to 90 mm in diameter. For scintigraphic studies, the overall sensitivity and specificity was 83% and 84%, respectively. However, sensitivity for palpable lesions was 100%. The smallest detectable tumor measured 9 mm in diameter and could be visualized only in the planar scintigram. Using Tc-99m MIBI, axillary lymph node metastases could be detected with a sensitivity of 82%. Scintigraphy with Tc-99m MIBI has a high diagnostic accuracy for the detection of primary breast cancer in patients with a palpable mass. Scintimammography may be used as a complementary method to mammography and help to decrease the number of unnecessary breast biopsies.
- Published
- 1996
- Full Text
- View/download PDF
16. Scintimammography with technetium-99m methoxyisobutylisonitrile: comparison with mammography and magnetic resonance imaging.
- Author
-
Palmedo H, Grünwald F, Bender H, Schomburg A, Mallmann P, Krebs D, and Biersack HJ
- Subjects
- Biopsy, Breast pathology, Breast Neoplasms diagnosis, Contrast Media, Female, Gadolinium DTPA, Humans, Magnetic Resonance Imaging, Mammography, Middle Aged, Organometallic Compounds, Palpation, Pentetic Acid analogs & derivatives, Predictive Value of Tests, Prospective Studies, Sensitivity and Specificity, Tomography, Emission-Computed, Single-Photon, Breast diagnostic imaging, Breast Neoplasms diagnostic imaging, Technetium Tc 99m Sestamibi
- Abstract
The aim of the study was to compare the diagnostic accuracy of scintimammography with technetium-99m methoxyisobutylisonitrile (MIBI; SMM) in the detection of primary breast cancer with that of mammography (MM) and magnetic resonance imaging (MRI). Fifty-six patients with suspected lesions detected by palpation or MM were included in the study. Within the 4 weeks preceding excisional biopsy, MM and MRI were performed in all patients. Between 5 and 10 min after the injection of 740 MBq 99mTc-MIBI, SMM in the prone position was performed. In the total group of 56 patients, 43 lesions were palpable, while 13 were non-palpable but were detected by MM. Breast cancer was confirmed by histopathology in 27 of the patients (22 palpable and 5 non-palpable carcinomas). The tumour size ranged from 6 to 80 mm in diameter. For non-palpable lesions, the sensitivity of SMM, MM and MRI was 60%, 60% and 100%, respectively, while the specificity was 75%, 25% and 50%, respectively. For palpable breast lesions, all methods showed high sensitivity (SMM 91%, MM 95%, MRI 91%) but SMM demonstrated significantly higher specificity (SMM 62%, MM 10%, MRI 15%). In two mammographically negative tumours (dense tissue), SMM showed a positive result. In comparison to MRI, one additional carcinoma could be diagnosed by SMM. It may be concluded that for palpable breast lesions, the diagnostic accuracy of SMM is superior to that of MM and MRI. Through the complementary use of SMM it is possible to increase the sensitivity for the detection of breast cancer and multicentric disease. In patients in whom the status of a palpable breast mass remains unclear, SMM may help to reduce the amount of unnecessary biopsies.
- Published
- 1996
- Full Text
- View/download PDF
17. Technetium-99m-MIBI scintimammography for suspicious breast lesions.
- Author
-
Palmedo H, Schomburg A, Grünwald F, Mallmann P, Krebs D, and Biersack HJ
- Subjects
- Adenocarcinoma diagnostic imaging, Adenocarcinoma epidemiology, Breast Neoplasms epidemiology, Diagnosis, Differential, Evaluation Studies as Topic, Female, Fibroadenoma diagnostic imaging, Fibroadenoma epidemiology, Fibrocystic Breast Disease diagnostic imaging, Fibrocystic Breast Disease epidemiology, Humans, Lymphatic Metastasis, Middle Aged, Predictive Value of Tests, Prospective Studies, Sensitivity and Specificity, Tomography, Emission-Computed, Single-Photon, Breast Neoplasms diagnostic imaging, Technetium Tc 99m Sestamibi
- Abstract
Unlabelled: The aim of this study was to evaluate the diagnostic accuracy of scintimammography with 99mTc-MIBI in patients with suspected primary breast cancer as monitored by SPECT or planar imaging., Methods: Patients with a suspect lesion detected by palpation or mammography were entered in the study. Excisional biopsy was performed on all patients and a mammography was performed within three weeks prior to scintigraphy. All patients received intravenously 740 MBq 99mTc-MIBI in the arm, contralateral to the suspicious breast, and were subsequently examined in a prone position. At 5-10 min postinjection, planar images were obtained in both the lateral and anterior views with an acquisition time of 10 min. After planar imaging, SPECT imaging was performed using a two-head high-resolution gamma camera., Results: In the total patient group of 54 patients, 40 lesions were palpable and 14 were nonpalpable but were detected by mammography. Breast cancer was confirmed in 24 of the patients and 20 of the palpable masses were found to be carcinomas. The tumor size ranged from 6 to 90 mm in diameter. In scintigraphic studies, the overall sensitivity was 88% for planar imaging and 83% for SPECT. Specificity was 83% and 80%, respectively. Sensitivity for palpable lesions was 100%. The smallest detectable tumor measured was 9 mm in diameter and could only be visualized in the planar scintigram., Conclusion: Scintigraphy with 99mTc-MIBI is extremely sensitive for the detection of primary breast cancer in patients with a palpable mass. SPECT, however, did not improve the diagnostic accuracy over planar scintimammography.
- Published
- 1996
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.